background
coronaviru
infecti
diseas
develop
global
pandem
essenti
investig
clinic
characterist
uncov
potenti
risk
factor
sever
diseas
reduc
overal
mortal
rate
method
sixtyon
critic
patient
admit
intens
care
unit
icu
sever
nonicu
patient
huoshenshan
hospit
wuhan
china
includ
studi
medic
record
includ
demograph
platelet
count
heparininvolv
treatment
heparininduc
thrombocytopenia
hit
relat
laboratori
test
fatal
outcom
patient
analyz
compar
survivor
nonsurvivor
find
sixtyon
critic
patient
treat
icu
includ
survivor
nonsurvivor
fortyon
percent
sever
thrombocytopenia
platelet
count
plt
less
l
platelet
decreas
compar
baselin
patient
fatal
outcom
among
nonsurvivor
sever
thrombocytopenia
compar
among
survivor
moreov
continu
renal
replac
therapi
crrt
could
induc
signific
decreas
plt
critic
crrt
patient
result
fatal
outcom
addit
high
level
antibodi
marker
hit
observ
icu
patient
surprisingli
hit
occur
patient
heparin
exposur
crrt
also
patient
suggest
spontan
hit
may
occur
coronaviru
infecti
diseas
caus
novel
coronaviru
structur
relat
viru
caus
sever
acut
respiratori
syndrom
sar
develop
global
pandem
two
million
infect
death
current
mortal
reach
high
franc
itali
china
approxim
patient
mild
case
wherea
sever
case
acut
respiratori
distress
syndrom
ard
requir
ventil
support
critic
patient
need
intens
care
unit
icu
admiss
surviv
rate
critic
patient
elderli
peopl
peopl
underli
medic
condit
higher
risk
develop
seriou
complic
septic
shock
ard
acut
kidney
injuri
aki
fulmin
myocard
approxim
death
occur
among
peopl
age
year
china
new
infecti
diseas
character
sever
acut
respiratori
injuri
hyperinflammationrel
syndrom
poor
prognosi
predictor
uncov
retrospect
studi
includ
hypercytokinemia
significantli
elev
hallmark
inflammatori
respons
eg
creactiv
protein
crp
serum
ferrin
organ
failur
eg
aspart
alanin
transaminas
ast
alt
cardiac
troponin
blood
urea
nitrogen
bun
rnaemia
addit
sever
thrombocytopenia
elev
neutrophil
reduc
lymphocyt
also
report
extens
critic
patient
combin
progress
pulmonari
lesion
ct
imag
find
may
help
establish
appropri
clinic
guidanc
critic
ill
case
low
platelet
count
thrombocytopenia
associ
increas
risk
sever
diseas
mortal
patient
sar
reason
fulli
understood
heparininduc
thrombocytopenia
hit
wellrecogn
complic
heparin
therapi
occur
spontan
independ
heparin
hit
caus
bind
heparin
platelet
factor
releas
activ
platelet
antibodi
complex
induc
patient
subsequ
complex
bind
platelet
receptor
induc
platelet
activ
aggreg
activ
coagul
pathway
eventu
loss
circul
platelet
prothrombot
state
nevertheless
hit
induc
absenc
proxim
heparin
exposur
socal
spontan
hit
neg
charg
bacteri
nucleic
acid
hypersulf
chondroitin
patient
develop
spontan
hit
proxim
episod
infect
major
surgeri
studi
critic
icu
patient
sever
nonicu
patient
hospit
februari
april
huoshenshan
hospit
wuhan
china
emerg
hospit
establish
patient
includ
found
substanti
percentag
critic
icu
patient
show
sever
progress
decreas
platelet
count
often
fatal
outcom
analysi
show
elev
level
antibodi
hit
antibodi
critic
patient
suggest
hit
contribut
greatli
fatal
outcom
patient
critic
condit
sixtyon
patient
confirm
critic
condit
admit
wuhan
huoshengshan
hospit
hospit
establish
sever
critic
patient
februari
march
everi
patient
stay
intens
care
unit
three
day
herein
refer
icu
patient
least
three
consecut
detect
platelet
count
data
anoth
patient
sever
never
stay
icu
randomli
select
hospit
herein
refer
nonicu
patient
diagnosi
made
accord
chines
clinic
guidanc
viral
rna
confirm
patient
revers
transcript
realtim
pcr
clinic
laboratori
hospit
except
patient
rnaposit
admiss
hospit
turn
neg
hospit
clinic
outcom
record
april
routin
blood
test
coagul
test
perform
hospit
laboratori
admiss
hospit
demograph
data
patient
includ
inform
age
gender
shown
supplementari
tabl
studi
approv
ethic
committe
huoshenshan
hospit
wuhan
china
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
human
complex
antibodi
igg
detect
use
antigensandwich
enzymelink
immunosorb
assay
elisa
kit
produc
jonln
biolog
compani
cat
briefli
serum
ad
microwel
coat
complex
incub
wash
wash
buffer
horseradish
peroxidas
hrp
conjug
ad
incub
care
wash
hrp
activ
determin
abil
convert
substrat
tmb
blue
product
amount
hit
antibodi
quantifi
use
set
calibr
standard
provid
manufactur
serum
level
determin
twoantibodi
sandwich
elisa
similar
hit
assay
assay
micropl
well
coat
antibodi
captur
antibodi
presenc
patient
serum
quantifi
hrpconjug
antibodi
surviv
rate
qualit
data
comparison
among
differ
group
pvalu
calcul
use
chisquar
test
fisher
exact
test
r
version
ttest
use
determin
signific
differ
p
consid
statist
signific
data
present
mean
sd
mean
sem
address
fact
mani
patient
icu
receiv
transfus
complet
blood
count
data
hospit
analyz
expect
decreas
red
blood
cell
count
rbc
hemoglobin
rgb
observ
icu
patient
figur
surpris
progress
sever
decreas
platelet
count
plt
occur
critic
icu
patient
fatal
outcom
figur
tabl
rare
occur
icu
survivor
figur
tabl
nonicu
patient
sever
figur
shown
tabl
sever
thrombocytopenia
l
observ
nonicu
patient
wherea
occur
icu
patient
icu
nonsurvivor
moreov
approxim
icu
nonsurvivor
plt
count
less
l
compar
among
icu
survivor
tabl
notabl
icu
nonsurvivor
critic
thrombocytopenia
plt
less
l
late
phase
day
death
diseas
figur
tabl
signific
plt
decreas
decreas
last
sampl
date
compar
admiss
date
also
observ
icu
nonsurvivor
neither
icu
survivor
nonicu
patient
figur
analysi
variat
plt
nine
icu
nonsurvivor
patient
hospit
detail
found
plt
began
decreas
day
onset
ill
progress
decreas
critic
condit
next
day
figur
countermeasur
transfus
blood
cell
platelet
fresh
frozen
plasma
ffp
show
littl
effect
plt
decreas
figur
suggest
progress
plt
exhaust
occur
die
patient
unknown
reason
blood
coagul
factor
exhaust
administr
tocilizumab
tcz
inhibitor
inflamm
suggest
use
chines
guidelin
seem
abl
revers
chang
plt
transient
patient
except
sever
thrombocytopenia
recur
day
administr
figur
control
one
fifteen
icu
survivor
patient
show
extrem
low
plt
without
progress
plt
decreas
figur
result
suggest
sever
thrombocytopenia
progress
platelet
count
decreas
occur
critic
patient
fatal
outcom
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
continu
renal
replac
therapi
crrt
commonli
use
icu
correct
metabol
acidosi
remov
cytokin
indic
critic
patient
howev
among
crrt
patient
crrt
trigger
sharp
decreas
plt
patient
figur
notabl
among
crrttreat
patient
patient
survivor
crrt
moder
pneumonia
critic
kidney
failur
patient
viral
rnaneg
time
admiss
hospit
show
declin
plt
crrt
treatment
compar
crrt
treat
patient
figur
suggest
crrt
could
induc
signific
decreas
plt
critic
patient
sever
characterist
pneumonia
accordingli
serious
reduc
plt
less
l
observ
crrt
patient
crrt
therapi
decreas
level
less
l
day
crrt
treatment
figur
compar
noncrrt
icu
patient
nonicu
patient
decreas
plt
less
l
tabl
moreov
signific
plt
fall
also
observ
crrt
patient
compar
noncrrt
icu
patient
figur
particularli
noncrrt
icu
survivor
figur
noncrrt
patient
averag
decreas
plt
nonsurviv
patient
compar
ie
increas
survivor
figur
indic
signific
decreas
plt
may
risk
factor
high
mortal
concert
sever
thrombocytopenia
icu
patient
treat
crrt
die
within
three
day
post
crrt
four
die
within
day
post
crrt
treatment
figur
surviv
patient
admit
icu
critic
kidney
failur
sever
pneumonia
mention
surviv
rate
patient
receiv
crrt
treatment
far
lower
icu
patient
receiv
crrt
treatment
figur
left
panel
data
collect
suggest
crrt
might
contribut
high
mortal
critic
patient
induc
sever
thrombocytopenia
progress
decreas
plt
icu
patient
suggest
possibl
hit
sinc
lowmolecularweight
heparin
enoxaparin
lmwh
routin
use
anticoagul
crrt
therapi
hospit
lmwh
also
wide
use
elderli
bedridden
icu
patient
prevent
thrombosi
manag
coagulopathi
dissemin
intravascular
coagul
dic
icu
patient
without
crrt
patient
receiv
lmwh
higher
statist
signific
percentag
patient
sever
thrombocytopenia
l
patient
without
lmwh
vs
tabl
lower
surviv
rate
also
observ
noncrrt
patient
expos
heparin
compar
noncrrt
patient
without
heparin
exposur
vs
figur
right
panel
consist
fact
smaller
dose
lmwh
appli
nonicu
patient
flush
central
venou
cathet
mild
plt
decreas
found
four
nonicu
patient
receiv
heparin
lowest
number
l
figur
progress
plt
decreas
level
around
l
observ
one
four
patient
find
indic
heparin
exposur
may
risk
factor
sever
heparin
exposur
correl
sever
thrombocytopenia
suggest
hit
might
respons
sever
thrombocytopenia
substanti
hypothesi
hit
antibodi
complex
marker
hit
analyz
use
elisa
kit
higher
level
hit
antibodi
detect
avail
sera
icu
patient
sera
icu
patient
alway
unavail
due
death
discharg
mild
patient
convalesc
patient
healthi
peopl
figur
surpris
elev
hit
antibodi
level
also
observ
icu
patient
crrt
implement
heparin
exposur
noncrrt
patient
suggest
heparin
preexposur
absolut
requir
induc
hit
critic
patient
figur
accordingli
among
nonsurvivor
seven
patient
experienc
progress
decreas
plt
four
plt
decreas
figur
consist
elev
hit
antibodi
complement
activ
shown
accumul
also
observ
patient
figur
concentr
serum
hit
antibodi
larg
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
correl
level
figur
report
releas
heparin
master
cell
could
induc
complement
activ
may
indic
potenti
role
endogen
heparin
spontan
hit
viral
infect
moreov
report
studi
higher
percentag
neutrophil
observ
nonsurviv
critic
patient
may
contribut
sever
hit
surviv
critic
patient
figur
addit
laboratori
test
venou
arteri
complic
includ
deep
venou
thromboembol
complic
observ
patient
die
autopsi
among
three
nonsurviv
icu
patient
receiv
autopsi
hyalin
thrombu
thrombi
found
patient
show
progress
decreas
plt
bleed
lung
tissu
thrombi
observ
patient
constantli
low
plt
count
figur
furthermor
obviou
bleed
thrombi
occur
patient
signific
decreas
plt
count
lowest
point
well
l
confirm
vein
thromboembol
vte
icu
patient
ct
pulmonari
angiographi
ctpa
ultrasonographi
also
report
recent
although
platelet
activ
assay
perform
limit
capac
huoshenshan
hospit
current
result
still
strongli
suggest
hit
spontan
hit
induc
viru
secondari
bacteri
infect
may
occur
would
significantli
boost
aggrav
heparin
exposur
high
dose
therebi
result
fatal
outcom
sever
thrombocytopenia
thrombosisinduc
system
clot
sever
critic
ill
patient
result
complic
factor
greatli
enhanc
risk
entri
infect
may
directli
lead
endotheli
damag
therebi
trigger
platelet
activ
aggreg
coagulopathi
mechan
similar
report
sarscov
moreov
seriou
complic
also
result
elev
level
ddimer
fibrin
degrad
product
indic
dic
antiphospholipid
antibodi
autoantibodi
induc
thrombi
larg
vein
arteri
factor
contribut
increas
platelet
consumpt
eventu
thrombocytopenia
show
hit
occur
frequent
sever
patient
receiv
heparininvolv
therapi
spontan
hit
wide
use
diagnost
criteria
hit
includ
hit
antibodi
complex
heparinoid
heparin
similar
glycosaminoglycan
hit
antibodiesmedi
platelet
activ
progress
plt
decreas
least
baselin
onset
thrombocytopenia
occur
within
five
ten
day
initi
heparin
hour
heparin
reexposur
thrombosi
patient
treat
heparin
studi
sever
thrombocytopenia
plt
l
plt
decreas
rapid
decreas
upon
crrt
treatment
high
level
heparin
exposur
high
level
hit
antibodi
venou
arteri
even
deep
venou
thrombi
patient
die
basic
fit
clinic
definit
hit
notabl
hit
antibodi
progress
decreas
plt
also
detect
patient
ie
crrt
heparin
exposur
even
nonicu
patient
figur
indic
occurr
spontan
hit
patient
probabl
result
viru
secondari
bacteri
infect
staphylococcu
aureu
escherichia
coli
sever
tissu
damag
immun
thrombocytopen
purpura
itp
autoimmun
disord
similar
hit
report
coronaviru
infect
patient
nonicu
patient
progress
plt
decreas
rare
occur
either
less
sever
viral
secondari
bacteri
infect
far
lower
level
heparin
exposur
sinc
heparin
primarili
administ
flush
central
venou
cathet
prevent
blood
clot
treatment
venou
thrombosi
icu
patient
moder
plt
decreas
nonicu
patient
hit
transient
recov
convalesc
although
protect
effect
heparininvolv
anticoagul
sever
report
tang
et
al
potenti
risk
hit
caution
use
treat
critic
icu
patient
high
dosag
find
strongli
indic
occurr
hit
sever
although
current
evid
fulli
meet
rigor
definit
spontan
hit
propos
warkentin
et
al
limit
medic
laboratori
capac
de
novo
establish
huoshenshan
hospit
patient
platelet
serotoninreleas
assay
sra
highli
pathogen
hit
sera
contain
heparindepend
heparinindepend
platelet
activ
antibodi
perform
later
provid
solid
evid
hit
covid
patient
hit
igg
could
gener
earli
first
day
heparin
treatment
indic
preimmun
antigen
highli
similar
complex
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
preimmun
may
result
spontan
hit
preimmun
patient
subsequ
exposur
high
dosag
heparin
anticoagul
therapi
crrt
coagul
control
significantli
boost
preform
b
cell
via
lot
complex
therebi
prompt
activ
consumpt
platelet
result
progress
thrombocytopenia
extens
coagul
deterior
patient
may
explain
high
mortal
critic
ill
patient
receiv
crrt
import
support
treatment
critic
ill
patient
sepsi
aki
crrt
use
effici
remov
proinflammatori
mediat
accumul
blood
maintain
fluid
balanc
hemodynam
unstabl
patient
recommend
renal
failur
renal
replac
therapi
chines
clinic
guidanc
howev
accumul
clinic
data
show
nearli
survivor
among
critic
patient
receiv
crrt
treatment
indic
patient
benefit
crrt
show
seriou
hit
may
respons
high
fatal
crrt
critic
patient
therefor
suggest
clinic
occurr
hit
patient
especi
critic
patient
detect
monitor
care
patient
strongli
suspect
hit
physician
stop
heparininvolv
therapi
initi
altern
anticoagul
heparin
platelet
aggreg
inhibitor
prostacyclin
direct
thrombin
inhibitor
eg
lepirudin
nonheparin
glycosaminoglycan
antifactor
xa
activ
eg
fondaparinux
region
citrat
anticoagul
avoid
risk
hitinduc
thrombosi
patient
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
inform
consent
approv
ethic
committe
huoshensan
hospit
obtain
collect
blood
sampl
patient
data
shown
mean
sem
analyz
use
twotail
student
ttest
differ
consid
signific
p
indic
data
present
mean
sem
analyz
use
twotail
student
ttest
differ
consid
signific
p
p
indic
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
sever
thrombocytopenia
platelet
l
b
moder
thrombocytopenia
platelet
l
l
c
contain
nonsurvivor
critic
thrombocytopenia
platelet
less
l
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
